Nimblegen Systems Raises Another $8.2 Million in Financing
News Dec 05, 2005
NimbleGen Systems Inc. has announced the closing of a private venture financing in the amount of $8.2 million. The Company has raised a total of $50 million since its inception in 1999.
"NimbleGen is uniquely positioned in the microarray market with both high probe density and long oligos," said Sanjiv Arora, NimbleGen Director at Cargill Ventures.
"The company has made enormous strides in the past year, becoming the ChIP-chip market leader, launching its CGH platform with the highest resolution in the market, and pushing the frontier of emerging, novel applications."
Dr. David Lowe, NimbleGen Director at Skyline Ventures, agreed, "We’re confident in NimbleGen’s technology and management."
"NimbleGen Systems has assembled a world class team of managers and scientists who have done an outstanding job of positioning the company for rapid growth with their technical accomplishments and strategic relationships, serving customers’ needs in new and existing markets."
"We are grateful for the support our investors have shown as NimbleGen continues to address issues related to rapid growth," said NimbleGen President and CEO Dr. Stanley Rose.
"They share our excitement over the opportunity we see to develop and leverage leading positions in a variety of emerging markets involving genetic analysis."
"We have been growing very rapidly over the past two quarters, and our investors have stepped forward to provide the resources needed to take NimbleGen to the next level of commercial success."
NimbleGen is working to enable High-Definition GenomicsSM, a rapidly growing approach to genomic science that provides enhanced detail of genetic variation and clarity of complex data sets.
The flexibility of NimbleGen’s microarray platform combined with its products of expression, ChIP-chip, CGH, and comparative genome sequencing provide the basis for new avenues of basic genomics research as well as diagnostics and therapeutic development.
All of the company’s existing venture capital and institutional investors participated in the round, including Cargill Ventures, Skyline Ventures, Topspin Partners, Tactics II Investments LLC, Venture Investors LLC, Baird Venture Partners, The Wisconsin Alumni Research Foundation (WARF) and the State of Wisconsin Investment Board.
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.
Bubble formation is typically a much more random process than liquid droplet formation, yet the generation of uniform drops and bubbles is very desirable in microfluidics. Researchers have now shown that under certain conditions, bubbles can also be coaxed to form spheres as perfectly matched as droplets.READ MORE